Claims for Patent: 10,780,055

Summary for Patent: 10,780,055

Title:	Delayed release deferiprone tablets and methods of using the same
Abstract:	The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Inventor(s):	Sherman; Bernard Charles (Toronto, CA), Spino; Michael (Pickering, CA)
Assignee:	Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:	16/171,173
Patent Claims:	1. A tablet for oral administration of deferiprone to a human subject, wherein the tablet comprises: (a) a core comprising deferiprone in a therapeutically effective amount and an enteric polymer in an amount of about 1% to about 20% by weight of the core, and (b) an enteric coating, wherein the tablet is scored such that it can be administered as a whole tablet or a half tablet and wherein if the tablet is administered as two half tablets then the two half tablets are bioequivalent to one whole tablet in either the fasted state or the fed state. 2. The tablet of claim 1, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof. 3. The tablet according to claim 1, wherein a total daily dose of the tablet administered twice daily is bioequivalent in the steady state to the total daily dose of an immediate release tablet comprising deferiprone administered three times daily. 4. The tablet according to claim 1, wherein a single dose of the tablet provides a mean AUCI/C.sub.max ratio between 3.5 hours and 6.0 hours in fasted state and/or fed state when the tablet is administered to human subjects. 5. The tablet according to claim 4, wherein the tablet comprises 1000 mg deferiprone. 6. The tablet according to claim 5, wherein a single dose of the 1000 mg tablet provides a mean C.sub.max between 2.670 and 13.232 .mu.g/mL when the tablet is administered to human subjects in a fasted state. 7. The tablet according to claim 5, wherein a single dose of the 1000 mg tablet provides a median T.sub.max between 1.33 and 4.00 hours when the tablet is administered to human subjects in a fasted state. 8. The tablet according to claim 5, wherein a single dose of the 1000 mg tablet provides a median T.sub.max between 2.00 and 8.00 hours when the tablet is administered to human subjects in a fed state. 9. The tablet according to claim 5, wherein a single dose of the 1000 mg tablet provides a ratio of AUCI/C.sub.max between 2.858 to 6.596 hours when the tablet is administered to human subjects in a fasted state. 10. The tablet according to claim 5, wherein a single dose of the 1000 mg tablet provides a ratio of AUCI/C.sub.max between 3.225 to 8.506 hours when the tablet is administered to human subjects in a fed state. 11. A tablet for oral administration of deferiprone comprising: (a) a core comprising deferiprone in a therapeutically effective amount and an enteric polymer in an amount of about 1% to about 20% by weight of the core, and (b) an enteric coating, the tablet being a whole tablet which is scored to facilitate breakage of the tablet into half tablets, wherein both the whole tablet and the half tablets display a delayed release dissolution profile. 12. The tablet according to claim 11, wherein the half tablets are bioequivalent to the whole tablet in either the fasted state or the fed state. 13. The tablet according to claim 11, wherein both the whole tablet and the half tablets exhibit dissolution below 20% at 60 minutes in 0.1 N HCl. 14. The tablet according to claim 11, wherein a single dose of the tablet provides a mean AUCI/C.sub.max ratio between 3.5 hours and 6.0 hours in fasted state and/or fed state when the tablet is administered to human subjects. 15. The tablet according to claim 11, wherein the tablet comprises 1000 mg deferiprone. 16. The tablet according to claim 15, wherein a single dose of the 1000 mg tablet provides a mean C.sub.max between 2.670 and 13.232 .mu.g/mL when the tablet is administered to human subjects in a fasted state. 17. The tablet according to claim 15, wherein a single dose of the 1000 mg tablet provides a median T.sub.max between 1.33 and 4.00 hours when the tablet is administered to human subjects in a fasted state. 18. The tablet according to claim 15, wherein a single dose of the 1000 mg tablet provides a median T.sub.max between 2.00 and 8.00 hours when the tablet is administered to human subjects in a fed state. 19. The tablet according to claim 15, wherein a single dose of the 1000 mg tablet provides a ratio of AUCI/C.sub.max between 2.858 to 6.596 hours when the tablet is administered to human subjects in a fasted state. 20. The tablet according to claim 15, wherein a single dose of the 1000 mg tablet provides a ratio of AUCI/C.sub.max between 3.225 to 8.506 hours when the tablet is administered to human subjects in a fed state. 21. The tablet according to claim 1, wherein the tablet releases less than 80% of the deferiprone within 60 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL water at 37.+-.0.5.degree. C. 22. The tablet of claim 21, wherein approximately 100% of the deferiprone is released within 90 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL at pH 6.8 or 4.5. 23. The tablet of claim 22, wherein approximately 50% of the deferiprone is released within 30 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL at pH 6.8 or 4.5. 24. A method for treating a subject with iron overload, comprising orally administering to the subject in need thereof the tablet of claim 1. 25. The method according to claim 24, wherein the subject suffers from thalassemia or myelodysplasia. 26. A method for treating a subject with a neurodegenerative disease, comprising orally administering to the subject in need thereof the tablet of claim 1. 27. The method of claim 26, wherein the subject suffers from Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's Ataxia, Pantothenate Kinase Associated Neurodegeneration (PKAN), or neurodegeneration with brain iron accumulation (NBIA). 28. The method according to claim 24, comprising a regimen of once daily or twice daily dosing (BID). 29. The method according to claim 24, wherein the tablet is administered to the subject as a whole tablet, a half tablet, or a combination thereof. 30. A tablet for oral administration comprising: (a) a core comprising 1000 mg of deferiprone, an enteric polymer, a pH adjusting agent, a glidant, and a lubricant; and (b) an enteric coating comprising a plasticizer, an anti-tacking agent, and an enteric polymer, the tablet being a whole tablet which is scored to facilitate breakage of the tablet into half tablets. 31. The tablet according to claim 11, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof. 32. The tablet according to claim 1, wherein both the whole tablet and the half tablets exhibit dissolution below 20% at 60 minutes in 0.1 N HCl. 33. The tablet according to claim 30, wherein both the whole tablet and the half tablets exhibit dissolution below 20% at 60 minutes in 0.1 N HCl. 34. The tablet according to claim 11, wherein the tablet releases less than 80% of the deferiprone within 60 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL water at 37.+-.0.5.degree. C. 35. The tablet according to claim 34, wherein approximately 100% of the deferiprone is released within 90 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL at pH 6.8 or 4.5. 36. A method for treating a human subject with iron overload, comprising orally administering to the subject in need thereof the tablet of claim 30, wherein the subject is administered the tablet two times per day. 37. The method according to claim 36, wherein the subject suffers from a neurogenic disease.